上皮-间质转换
胰腺癌
癌症研究
甲基化
组蛋白
癌症
表观遗传学
化学
细胞生物学
生物
医学
内科学
转移
生物化学
基因
作者
Brooke A. Brown,Paul J. Myers,Sara J. Adair,Jason R. Pitarresi,Shiv K. Sah‐Teli,Logan A. Campbell,William S. Hart,Michelle C. Barbeau,Kelsey Leong,Nicholas Seyler,William J. Kane,Kyoung Eun Lee,Edward B. Stelow,Marieke Jones,M. Celeste Simon,Peppi Koivunen,Todd W. Bauer,Ben Z. Stanger,Matthew J. Lazzara
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2024-03-12
卷期号:84 (11): 1764-1780
被引量:3
标识
DOI:10.1158/0008-5472.can-22-2945
摘要
The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) plays a key role in tumor progression and response to therapy. The dense PDAC stroma causes hypovascularity, which leads to hypoxia. Here, we showed that hypoxia drives long-lasting epithelial-mesenchymal transition (EMT) in PDAC primarily through a positive-feedback histone methylation-MAPK signaling axis. Transformed cells preferentially underwent EMT in hypoxic tumor regions in multiple model systems. Hypoxia drove a cell autonomous EMT in PDAC cells, which, unlike EMT in response to growth factors, could last for weeks. Furthermore, hypoxia reduced histone demethylase KDM2A activity, suppressed PP2 family phosphatase expression, and activated MAPKs to post-translationally stabilize histone methyltransferase NSD2, leading to an H3K36me2-dependent EMT in which hypoxia-inducible factors played only a supporting role. Hypoxia-driven EMT could be antagonized in vivo by combinations of MAPK inhibitors. Collectively, these results suggest that hypoxia promotes durable EMT in PDAC by inducing a histone methylation-MAPK axis that can be effectively targeted with multidrug therapies, providing a potential strategy for overcoming chemoresistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI